IL18 and type 2 diabetes mellitus: Further, in human patients with T2DM, the NLRP3 inflammasome is activated, leading to the upregulation of IL-1β and IL-18 [220], with a receptor agonist of the latter currently being tested in clinical trials for the treatment of T2DM [221].